M&A Deal Summary |
|
|---|---|
| Date | 2021-04-23 |
| Target | Integrated Rehab and Performance |
| Sector | Consumer Services |
| Buyer(s) | Ketamine One |
| Deal Type | Add-on Acquisition |
| Deal Value | 1M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2017 |
| Sector | Business Services |
Ketamine One is a single-purpose company focused in mental health. In 2021, the Company has acquired a network of 14 national medical cannabis clinics as well as KGK Science Inc., a leading North American contract research organization that provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. Ketamine One was founded in 2017 and is headquartered in Vancouver, Canada.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Consumer Services) | 1 of 1 |
| Type (Add-on Acquisition) | 1 of 1 |
| State (British Columbia) | 1 of 1 |
| Country (Canada) | 1 of 2 |
| Year (2021) | 1 of 2 |
| Size (of disclosed) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-27 |
KGK Science
London, Ontario, Canada Founded in 1997, KGK Science is a contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis, and emerging psychedelic industries. For over 23 years, the business has successfully helped hundreds of companies with custom-designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services, and consulting services. On an approximate basis, the business to date has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database, and collected 10 million data points. |
Buy | $17M |
